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Abstract: In this study, we compared plasma levels and the diagnostic utility of hematopoietic growth factors
(HGFs) with SCC-Ag in cervical cancer patients in relation to control groups and cervical intraepithelial neo-
plasia (CIN) patients and healthy subjects. Pretreatment plasma levels of HGFs (SCF, GM-CSF, G-CSF and
M-CSF) were determined by the use of immunoenzyme assay (ELISA), and SCC-Ag by chemiluminescent
microparticle immunoassay (CMIA). Significantly different concentrations of GM-CSF, G-CSF and M-CSF
were observed in the group of patients with cervical cancer and CIN compared to the healthy controls. Signifi-
cant differences in plasma levels of GM-CSF and M-CSF between cervical cancer and benign lesions patients
were also found. The HGFs and SCC-Ag diagnostic specificities received high values. The diagnostic sensitivity
and the predictive value of a positive and negative test result were higher for M-CSF than for antigen SCC in the
cancer group. The M-CSF area under the ROC curve (AUC) was the largest from hematopoietic cytokines and
SCC-Ag. These results suggest the potential utility of M-CSF as a good candidate for a marker of cervical cancer
as well as benign lesions of this organ (CIN). (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 2, 213–219)
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Introduction
Cervical cancer is a leading cause of morbidity and
mortality among women worldwide, especially in de-
veloping countries [1]. Findings from clinical and ep-
idemiologic research convincingly support human
papillomavirus (HPV) as the major risk factor for
carcinoma of the cervix [2]. Promiscuity, smoking his-
tory, and low socio-economic status have also been
established as risk factors for this malignancy [3].
The Bethesda System (TBS), which was formu-
lated to standardize the reporting of the Papanico-
laou test (known as Pap smear) results, is the most
important diagnostic technique for detecting pre-in-
vasive cervical cancer [3]. Some antigens have also
been measured in the sera of patients with this gyne-
cological cancer and have been related to the clinical
course of disease [4].
Stem cell factor (SCF), granulocyte-macrophage-
colony stimulating factor (GM-CSF), granulocyte-col-
ony stimulating factor (G-CSF) and macrophage-col-
ony stimulating factor (M-CSF) also known as colo-
ny stimulating factor-1 (CSF-1) are members of the
group of cytokines called hematopoietic growth fac-
tors (HGFs). Their biological role is to regulate the
proliferation, mobility, survival and differentiation of
hematopoietic progenitor cells [5]. Moreover, many
human non-hematopoietic tumors have been shown
to express increased levels of HGFs. Furthermore,
these cytokines play a role in the pathogenesis of can-
cer disease [6–8].
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M-CSF, its receptor (M-CSFR) and c-fms (proto-
oncogene encodes a transmembrane glycoprotein
which is identical to the receptor for M-CSF) overex-
pressions were confirmed on the lines of cervical can-
cer in comparison with the patients with benign le-
sions (CIN) and to the control group. The blockade
of M-CSFR resulted in the inhibition of tumor growth
and the intensification of the apoptosis processes in
cancer cells [9, 10]. The production of G-CSF and
GM-CSF has been demonstrated in a number of non-
hematologic malignancies including tumors of the
cervix [11–13]. Tissue expression of high levels of
G-CSF by tumor cells, or elevated levels of G-CSF
in patient serum samples, have been found to be as-
sociated with an aggressive malignant nature of the
tumor and poor patient outcomes [14]. The most pop-
ular theory which explains the aggressive nature
of G-CSF-associated cancers is the autocrine stimu-
lation of tumor growth by tumor cells which secrete
G-CSF and carry its receptor on their surface [12, 14].
The presence of receptors for SCF has also been con-
firmed on the lines of ovarian and cervical cancer
cells [8, 15].
Cervical intraepithelial neoplasia (CIN) is a mor-
phologically defined lesion associated with the de-
velopment of cervical carcinoma [16]. There is still
little knowledge concerning plasma levels of hemato-
poietic cytokines in subjects with benign lesions of
this organ.
The aim of this study was to determine the plas-
ma level and the diagnostic utility of selected HGFs
(SCF, GM-CSF, G-CSF, M-CSF) in comparison with
the commonly accepted tumor marker (SCC-Ag) in
cervical cancer patients in relation to the control
groups, cervical intraepithelial neoplasia patients, and
healthy controls. Additionally, the diagnostic criteria
and receiver-operating characteristics curve (ROC)
for the tested cytokines and SCC-Ag were defined.
Material and methods
Patients. The study consisted of 50 patients with squamous
cell carcinoma (SCC) of the cervix (women aged 25–77;
years SD = 12.70) diagnosed by the Gynecology group. The
control groups comprised 30 cervical intraepithelial neo-
plasia (CIN) patients (women aged 23–75; years SD = 13.65)
and 45 healthy volunteers (women aged 23–72 years; years
SD = 12.74). The cervical cancer patients and the control group
(benign lesions) were treated in the Department of Gynecolo-
gy, Medical University Hospital in Białystok, Poland between
2005 and 2009. None of the patients had received chemo-
or radiotherapy before blood sample collection.
The pretreatment staging procedures included: a cyto-
logical examination according to the TBS system, physical
and blood examinations and ultrasound scanning. Cervical
cancer and CIN histopathology was established in all cases.
The healthy women group also underwent a gynecological,
including a cytological, examination according to the TBS
system prior to blood collection. In addition, a reproduc-
tive organ ultrasound scan was performed where necessary.
Table 1 shows the tested groups. The clinical stages and his-
tological classification based on the criteria of the Interna-
tional Federation of Gynecology and Obstetrics (FIGO) and
the World Health Organization (WHO) were as follows:
35 patients in stage I, and 15 in stage II of the disease.
The study was approved by the local Ethics Committee (num-
bers: R-I-003/408/2004; R-I-002/262/2010) and all the patients
gave informed consent for their participation in the study.
Biochemical analyses. Venous blood samples were collect-
ed from each patient into a heparin sodium tube, centri-
fuged at 1,000 rpm for 15 min. to obtain plasma samples,
and stored at –85°C until assayed. Hematopoietic cytokines
were measured with enzyme-linked immunosorbent assay
(ELISA) (Quantikine Human HGFs Immunoassay; R&D
Systems, Abingdon, UK), according to the manufacturer’s
protocols. The intra-assay coefficient of variation (CV%)
Table 1. Characteristics of cervical cancer patients and
control groups: cervical intraepithelial neoplasia (CIN)
patients and healthy subjects
Study group Number
of patients
Cervical cancer patients 50
(type squamous cell carcinoma)
Median age (range) 49 (25–77)
Tumor stage 0 (CIN III) 9
IA 12
IB 14
IIA 8
IIB 7
Depth of tumor invasion Tis 9
(T factor) T1 26
T2 15
Nodal metastases N0 50
(N factor)
Distant metastases M0 50
(M factor)
Cervical intraepithelial neoplasia 30
Median age (range) 46 (23–75)
Numbers:
CIN I 16
CIN II 14
Healthy subjects 45
Median age (range) 45 (23–72)
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of SCF is reported by the manufacturers to be 2.0% at
a mean concentration of 655 pg/ml, SD = 12.9, of GM-CSF
— to be 9.5% at a mean concentration of 3.68 pg/ml,
SD = 0.35, of G-CSF — to be 2.8% at a mean concentra-
tion of 280 pg/ml, SD = 7.8, of M-CSF — to be 3.4% at
a mean concentration of 227 pg/ml, SD = 7.7.
Plasma concentrations of SCC-Ag were measured by
chemiluminescent microparticle immunoassay (CMIA)
(Abbott, Chicago, IL, USA). The intra-assay CV for
SCC-Ag is reported by the manufacturer of the assay kit to
be 5.1% at a mean concentration of 1.42 ng/ml, SD = 0.072.
Statistical analysis. A preliminary statistical analysis (c2 test)
revealed that the distribution of cytokine and tumor mark-
er levels did not follow normal distribution. Consequently,
the Mann–Whitney U-test was used for statistical analysis.
The Spearman rank correlation was used in the correlation
analyses. Data was presented as median and range. Statisti-
cally significant differences were defined as comparisons
resulting in p < 0.05. The cut-off of HGFs (SCF — 969.30
pg/ml, GM-CSF — 1.38 pg/ml, G-CSF — 25.05 pg/ml and
M-CSF — 406.85 pg/ml) and SCC-Ag (1.80 ng/ml) were used
at the specificity higher than 95% (calculated from healthy
blood donors). Statistical analyses were conducted using the
STATISTICA 8 PL program (StatSoft Inc., Tulsa, OK, USA).
Additionally, the diagnostic criteria, such as sensitivity, speci-
ficity, predictive value of a positive (PV-PR) and negative
(PV-NR) test result, and the area under the ROC curve
(AUC), were determined. The construction of the ROC
curves was performed using GraphRoc Program for Windows.
Results
Table 2 shows the median and range of the investi-
gated HGFs and SCC-Ag in the tested groups. The
medians of GM-CSF, G-CSF and M-CSF (0.23 pg/ml,
20.05 pg/ml and 500.45 pg/ml respectively) as well as
SCC-Ag (1.10 ng/ml) in the group with cervical can-
cer, were statistically significantly different compared
to the healthy women group (0.15 pg/ml, 13.31 pg/ml;
290.82 pg/ml and 0.90 ng/ml respectively) (p < 0.001
for the above-mentioned cytokines and p = 0.040 for
antigen SCC respectively).
Similarly, the medians of GM-CSF (0.44 pg/ml),
G-CSF (19.60 pg/ml) and M-CSF (415.30 pg/ml) in
the group of CIN patients were statistically signifi-
cantly higher compared to the healthy subjects (p =
= 0.001; p < 0.001 and p = 0.024, respectively). We
Table 2. Plasma levels of hematopoietic cytokines and SCC-Ag in cervical cancer patients and in control groups: cervical
intraepithelial neoplasia patients (CIN) and healthy subjects
Cervical cancer Cervical intraepithelial neoplasia Healthy subjects
SCF [pg/ml]
Median 713.94 817.40 687.67
Range 384.81–1,136.55 479.65–922.53 398.60–1,020.82
p NS NS
GM-CSF [pg/ml]
Median 0.23*/** 0.44*
Range 0.03–4.45 0.03–3.14 0.15
p < 0.001/ = 0.004 = 0.001 0.03–2.35
G-CSF [pg/ml]
Median 20.05* 19.60*
Range 0.11–64.70 10.42–46.43 13.31
p < 0.001 < 0.001  3.11–29.55
M-CSF [pg/ml]
Median 500.45*/** 415.30*
Range 311.95–2,513.75 102.15–597.60 290.82
p < 0.001/ = 0.003 = 0.024 119.62–455.60
SCC-Ag [ng/ml]
Median 1.10* 1.00
Range 0.50–159.00 0.50–1.60 0.90
p = 0.040 NS 0.60–1.80
*Statistically significant compared to healthy subject group; **statistically significant compared to benign cervical lesions group;
NS — not significant
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also observed statistically significantly different plas-
ma levels of GM-CSF and M-CSF between the groups
of patients with cervical cancer and those with cervi-
cal intraepithelial neoplasia (0.23 pg/ml; 0.44 pg/ml
and 500.45 pg/ml; 415.30 pg/ml respectively) (Table 2).
Table 3 shows the HGFs’ diagnostic parameters
compared to SCC-Ag. Among all the tested param-
eters, only M-CSF showed the highest diagnostic
sensitivity (54%). The combined use of the tested
hematopoietic cytokines with antigen SCC result-
ed in an increase in sensitivity range. A maximum
diagnostic sensitivity (68%) was obtained for the
combination of M-CSF with SCC-Ag (Table 4). The
diagnostic specificities of the tested cytokines and
SCC-Ag received high equal values (93%) (Table 3).
The M-CSF predictive value of a positive test result
— PV-PR (90%) and predictive value of a negative
test result — PV-NR (65%) were higher than those
of SCC-Ag (81% and 53% respectively) (Table 3). The
combined use of the tested parameters resulted in
a decrease in the PV-PR to the range of 70%, and in
an increase in the PV-NR to the value of 71% (Table 4).
The area under the ROC curve indicates the clin-
ical usefulness of a tumor marker. In this study, the
M-CSF area (0.729) under the ROC curve (Figure 1)
is the largest from all HGFs, and far larger than that
of SCC-Ag (0.527). Moreover, only the area under
the ROC curve for M-CSF was statistically larger com-
pared to AUC = 0.5 (borderline of diagnostic useful-
ness of the test) (p < 0.001) (Figure 1).
Spearman rank correlation was used in the depen-
dence analysis between the investigated parameters.
There was no significant positive or negative correla-
tion between hematopoietic cytokines and SCC-Ag
concentrations in the cervical cancer or benign cervi-
cal lesions groups.
Discussion
Hematopoietic cytokines participate in hematopoie-
sis regulation, but they also appear to play a crucial
role in the development of cancers of different loca-
tions [17–20]. Elevated levels of HGFs have also been
demonstrated in the sera of patients with malignan-
cies of the reproductive organ, e.g. increased levels
of M-CSF in ovarian [21] or endometrial [22], and
G-CSF in cervical [11,13] cancer patients.
In this study, the plasma levels and the diagnostic
utility of selected hematopoietic cytokines were in-
vestigated. In the group of cervical cancer patients,
the plasma levels of GM-CSF, G-CSF and M-CSF
were statistically significantly different compared to
the healthy controls. These markers have been found
to be capable of discriminating cervical cancer patients
from those without malignant transformation. Com-
parable levels of these three cytokines (but without
statistical significance), were observed in the study of
Punnonen et al. [23], although a different type of re-
search material was used and the tested group of cer-
vical cancer patients was much smaller (n = 23). Sig-
nificant data for G-CSF has also been observed in
Table 4. Combined analysis of the diagnostic parameters of
hematopoietic cytokines with SCC-Ag
Diagnostic PV-PR PV-NR
sensitivity
 SCF + SCC-Ag 32% 73% 53%
GM-CSF + SCC-Ag 28% 70% 52%
M-CSF + SCC-Ag 68% 85% 71%
G-CSF + SCC-Ag 36%     75% 55%
Table 3. Analysis of the diagnostic parameters of hemato-
poietic cytokines and SCC-Ag
Diagnostic Diagnostic PV-PR PV-NR
sensitivity  specificity
 SCF  8% 93% 57% 48%
GM-CSF 6% 93% 50% 52%
M-CSF 54% 93% 90% 65%
G-CSF 16% 93% 73% 50%
SCC-Ag 26% 93% 81% 53%
Figure 1. ROC curves for SCF (AUC = 0.511; NS),
GM-CSF (AUC = 0.529; NS), G-CSF (AUC = 0.507; NS),
M-CSF (AUC = 0.729; p < 0.001) and SCC-Ag
(AUC = 0.527; NS) in cervical cancer patients
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the studies of other authors who additionally con-
firmed auto — and/or paracrine growth stimulation
of tumor cells by this cytokine in different histologi-
cal types of cervical cancer: carcinosarcoma [24],
small-cell [14] and squamous cell [11–13] carcinoma.
The tissue expression of high levels of G-CSF by tu-
mor cells or elevated levels of G-CSF in patient se-
rum samples have been found to be associated with
an aggressive malignant nature of the tumor and poor
patient outcomes [12, 14].
In the present study, which is a continuation of
our earlier investigation, a higher level of M-CSF was
also observed [25]. Furthermore, the key role of this
factor and its receptor in the initiation of carcinogen-
esis and tumor growth stimulation has been suggest-
ed in previous publications by other authors [9, 10].
The plasma concentrations of SCC-Ag were sig-
nificantly higher in the cervical cancer group com-
pared to the healthy controls. Our test data is in agree-
ment with the results of other researchers regarding
the diagnostic usefulness of antigen SCC in this ma-
lignancy [26–28]. Moreover, its prognostic signifi-
cance, both for recurrence-free and overall survival,
has been confirmed by other researchers in the early
stages of cervical cancer [29].
The distribution of SCF in the healthy donors and
in the cervical cancer patients was not significantly dif-
ferent. These research results are consistent with the
findings from our previous study [25], although Inoue
et al. [8] and Ohwada et al. [15] observed overexpres-
sion of mRNA for SCF and its receptor (c-kit) in cer-
vical cancer patients. Recently, the participation of this
receptor in cervical carcinogenesis associated with the
presence of human papillomavirus (HPV) has been
indicated [30]. Contradicting the results published in
these papers, Wang et al. [31] observed low expression
of c-kit, though in a very rare histological type of this
malignancy — small cell carcinoma.
In the group of CIN patients, the plasma levels of
GM-CSF, G-CSF and M-CSF were statistically sig-
nificantly higher compared to the healthy subjects.
Only these three cytokines were found to be capable
of discriminating patients from these two control
groups. Previously, other authors have found signifi-
cantly higher concentrations of M-CSF in patients
who either tested positive for human papillomavirus
or presented with benign lesions of the cervix. Rony
et al. [32] suggested that HPV oncogenes are not only
responsible for the immortalization of cervical epi-
thelial cells, but may also be responsible for the acti-
vation of M-CSF in CIN, which leads to the concom-
itant establishment of an autocrine loop. The inflam-
matory process and granulocytosis may be an expla-
nation for the higher levels of G-CSF both in benign
and malignant lesions of the cervix [13]. The investi-
gations of Zijlmans et al. [33] and Czygier et al. [34]
are in agreement with our data, and support the hy-
pothesis that GM-CSF (among other cytokines) in-
duces an inflammatory response which assists in tu-
mor growth and progression.
Our results revealed statistically considerably low-
er levels of GM-CSF in the group of cervical cancer
compared to the benign cervical lesions patients.
Some authors have observed a down-regulation of the
expression level of proinflammatory cytokines such
as GM-CSF in cervical cancer, but only in in vitro con-
ditions [35]. Interestingly, in our study M-CSF levels
in the cancer group were significantly higher com-
pared to CIN patients. Our results confirm the find-
ings of other researchers [9, 32]. On the other hand,
this data contradicts that of Punnonen et al. [23] who
postulated that malignant and benign tumors gener-
ally induce similar levels of cytokine production. How-
ever, these authors compared (among other gyneco-
logical malignancies) cervical cancer patients with
benign ovarian and uterine lesions patients only, and
purely in peritoneal fluids [23].
The ideal tumor marker should have a high sensitiv-
ity and a high specificity in order to discriminate cancer
patients from healthy subjects, or from patients with
benign conditions, and should be secreted into circula-
tion in concentrations proportional to tumor burden and
activity. It should also have high predictive values and
should correlate with the tumor stage. The criteria for
100% specificity and 100% sensitivity have to date not
been fulfilled by any of the known tumor markers. In
the current study, the M-CSF sensitivity was the highest
(54%) from all the tested parameters, higher even than
the sensitivity for SCC-Ag (26%).
The results of our study indicate that M-CSF can
be a better diagnostic tool than SCC-Ag in the early
diagnosis of cervical cancer. This confirms the results
obtained from our previous study concerning M-CSF,
although the tested group was only half as large [25].
The combined use of the tested cytokines result-
ed in an increase in the sensitivity to the maximum
range (68%) for the combination of M-CSF with
SCC-Ag. These results are very similar to those ob-
tained by us in previous studies, as well as to those of
other authors but in reference to cancers of various
locations, for example ovarian carcinoma [21, 36] or
pancreatic cancer [18].
The HGFs and SCC-Ag diagnostic specificities
were high — 93%. This is in agreement with our pre-
vious studies on this malignancy [25], and in the course
of breast [37] or ovarian cancer [36].
In the present investigation, M-CSF proved to have
higher PV-PR and PV-NR values than SCC-Ag (90%;
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65% and 81%; 53% respectively). Previously, we ob-
tained similar predictive values of hematopoietic cytok-
ines and SCC-Ag in this type of malignancy (83%; 69.7%
and 72.7%; 51% respectively), although a cervical can-
cer group consisted only of 25 patients [25]. The com-
bined use of the tested parameters resulted in a decrease
in the PV-PR and in an increase of the PV-NR to the
range of 71%. The results of the current study support
our previous findings concerning breast cancer [37].
The area under the ROC curve indicates the di-
agnostic power of a tumor marker. In the present
study, the ROC area of M-CSF was larger than the
SCC-Ag ROC area (AUC = 0.729 and AUC = 0.527
respectively). Additionally, we observed statistically
significantly larger AUC only for M-CSF, compared
to AUC = 0.5 (borderline of diagnostic usefulness of
the test). Our results showed that the diagnostic ac-
curacy of M-CSF in the group of cervical cancer pa-
tients were slightly lower than the diagnostic power
of M-CSF reported in our breast cancer study [37]
and by Mroczko et al. [38] or by Groblewska et al.
[18] in the course of colorectal and pancreatic can-
cer, and higher compared to non-small cell lung can-
cer [39]. The remainder of the selected cytokines dem-
onstrated a lower diagnostic power in patients with
cervical cancer than in patients with malignant tumors
of other locations [18, 38, 40].
Spearman rank correlation was used in the depen-
dence analyses between the investigated cytokines and
SCC-Ag. The plasma level of HGFs did not follow
the levels of the established gynecological tumor
marker. However, we reported earlier a positive cor-
relation between M-CSF and SCC-Ag, which may
have resulted from a different composition of the cer-
vical cancer group [25].
In summary, this is the first complete investiga-
tion comparing the diagnostic value of the measure-
ment of selected hematopoietic cytokines and the
commonly used tumor marker in patients with carci-
noma of the uterine cervix. M-CSF appears not to be
cancer selective, and alone it is not sufficient for the
diagnosis of cervical cancer, although it showed the
biggest diagnostic power from all the tested factors.
These results suggest a potential role for M-CSF as
a tumor marker for the early diagnosis of both cervi-
cal intraepithelial neoplasia and cervical cancer, es-
pecially in combination with SCC-Ag.
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